“We’re just humbled and pleased by the results this week as a starting point for therapies in COVID-19.” Gilead CEO Daniel O’Day discussed the positive results released this week from 2 remdesivir studies.
Vials of investigational coronavirus disease treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S. March 18, 2020. Picture taken March 18, 2020.said Thursday that it can produce "several million" rounds of its antiviral drug remdesivir next year to help patients fight the coronavirus.
The company expects to produce more than 140,000 rounds of its 10-day treatment regimen by the end of May and anticipates it can make 1 million rounds by the end of this year. "Our focus at this time is on both our work with remdesivir and our ongoing commitments to the people who depend on our medicines today," Gilead CEO Daniel O'Day said in the company's first-quarter earnings release.
On Wednesday, Gilead released preliminary results from its clinical trial on remdesivir, showing at least 50% of the patients treated with a five-day dosage of the drug improved. The clinical trial involved 397 patients with severe cases of Covid-19. The severe study is "single-arm," meaning it did not evaluate the drug against a control group of patients who didn't receive the drug.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead gets emergency FDA authorization for remdesivir to treat coronavirus, Trump saysThe Food and Drug Administration has granted emergency use authorization for Gilead’s remdesivir drug to treat the coronavirus, President Donald Trump announced Friday.
Read more »
FDA Authorizes Emergency Use of Gilead Drug Remdesivir for Covid-19 PatientsThe Food and Drug Administration’s move came after researchers reported that the Gilead drug shortened the recovery times in people who have fallen ill from the new coronavirus.
Read more »
Maker of coronavirus trial drug aims for wide distribution: Gilead CEOGilead Sciences , which manufactures remdesivir, is focused on making the experimental coronavirus drug accessible and affordable to as many people as possible once it is approved, Chief Executive Officer Daniel O'Day said on Friday.
Read more »
Gilead to work with partners to ramp up production of potential coronavirus treatmentGilead Sciences Inc , maker of the closely-watched experimental coronavirus drug remdesivir, on Thursday said it will work with international partners to expand production of the potential COVID-19 treatment.
Read more »
Gilead CEO on remdesivir: manufacturing, pricing for coronavirus drug - Business InsiderGilead plans to spend up to $1 billion to ramp up manufacturing of its coronavirus treatment, but execs dodged Wall Street's questions about turning a profit
Read more »
Fauci says leak concerns fueled his White House revelation of Gilead drug resultsConcerns over leaks compelled the top U.S. infectious disease official to reveal data on Gilead Sciences Inc’s experimental drug remdesivir, the first in a scientifically rigorous clincial trial to show benefit in treating COVID-19.
Read more »